Societal Impact of Metastatic Breast Cancer Treatment in Five European Countries

Five European countries (EU5) are covered in this dataset of supplementary tables for a peer-reviewed study on the societal impact of a medical intervention. The data includes country-level figures on breast cancer incidence, retirement age, life expectancy, productivity, costs, and fiscal impacts related to the drug trastuzumab deruxtecan. The dataset was authored by Foteini Tsotra and last updated on May 22, 2026.

Use Cases

• Modeling the fiscal impact of cancer treatments based on country-specific tax revenue and benefit expenditure data.
• Estimating productivity gains and losses in paid and unpaid work for health economic evaluations.
• Comparing healthcare and economic parameters, such as return-to-work rates and life expectancy, across European countries.
• Assessing the value of quality-adjusted life years (QALYs) within a societal impact framework.

Strengths

• Data is peer-reviewed supplementary material for a published journal article.
• Quantifies specific societal impacts, such as a €589 million gain in patient productivity and a €1.7 billion value for QALYs gained.
• Provides a multi-country perspective with data from five European nations.

Limitations

• Row count and column-level documentation are unknown, requiring inspection after download.
• The dataset is very small at 58.9 KB, indicating limited scope and likely summary-level data.
• Data may reflect the specific methodological framework and assumptions of the original study.

Provenance

Source

figshare, as supplementary materials for an article in the Journal of Comparative Effectiveness Research.

Collection Method

Likely compiled from published statistics and study models for the economic evaluation.

Freshness

Last updated 2026-05-22 10:40:58; freshness should be verified.

Geography

Five European countries (EU5).